A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin
Status:
Unknown status
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
Type two diabetes mellitus (T2DM) is a common, long term metabolic disorder characterised by
hyperglycaemia (high blood glucose) resulting from insulin resistance and relative insulin
insufficiency. The risk of developing insulin resistance and subsequently T2DM is increased
by being overweight and also through a sedentary lifestyle. As the onset can be gradual,
physiological damage may have occurred prior to diagnosis. Diabetes is associated with the
development of microvascular complications (diabetic nephropathy, neuropathy, and
retinopathy), and macrovascular complications (coronary artery disease, peripheral arterial
disease, and stroke). While there are many treatments available for T2DM, these complications
may still arise, leading to significant morbidity and mortality. There is therefore an urgent
need to identify novel signalling pathways that may contribute to the development of diabetes
related complications. The identification of these pathways may ultimately lead to the
development of new therapies targeting better blood glucose control and preventing these
subsequent complications.
Both animal and human studies have indicated that two endogenous peptides, apelin and relaxin
both act as vasodilators in the human cardiovascular system and could also have beneficial
action in T2DM. Therefore, we aim to carry out experimental medicine studies to test this
hypothesis, and explore the signalling pathway in the human vascular system.
Phase:
Phase 2
Details
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust